BioSpace News Archive

Reviva Pharmaceuticals Holdings, Inc. today reported financial results for the first quarter ended March 31, 2024 and summarized recent business highlights.

Akebia Therapeutics®, Inc. announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the 2nd Annual HCW Bioconnect Investor Conference on Monday, May 20th, 2024 at 3:00 p.m. ET.

Precision for Medicine, a global leader in biomarker-driven clinical research and development supporting life sciences companies, announced the completion of a major expansion to its laboratory campus in Frederick, Maryland.

ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2024.

Anumana today announced the appointment of Harry S. Palmin as chief financial officer (CFO).

Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 21, 2024, before the open of U.S. markets.

Delcath Systems, Inc. today reported financial results and business highlights for the first quarter ended March 31, 2024.

Cybin Inc. is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase, taking place May 21, 2024.

Zai Lab today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the supplemental Biologics License Application (sBLA) for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.